<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: Intramucosal <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> treatment is evolving </plain></SENT>
<SENT sid="1" pm="."><plain>Less-invasive therapies have emerged, necessitating review of safety, effectiveness, and determinants of long-term outcome after esophagectomy to clarify the role of this traditional, maximally invasive, and potentially harmful therapy </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: From January 1983 to January 2011, 164 patients underwent esophagectomy alone for intramucosal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancers</z:e> were subdivided by depth of invasion: lamina propria 50 (30%) and muscularis mucosa 114 (70%; inner 42 [26%], middle 16 [10%], and outer 56 [34%]) </plain></SENT>
<SENT sid="4" pm="."><plain>We assessed complications and esophagectomy-related mortality (safety) and <z:e sem="disease" ids="C0920420" disease_type="Neoplastic Process" abbrv="">cancer recurrence</z:e> (effectiveness), and identified determinants of long-term outcomes </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> (P = .005), larger <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (P &lt; .001), worse histologic grade (P &lt; .001), lymphovascular invasion (P &lt; .001), and overstaging (P = .02) were associated with deeper <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>One patient had regional <z:e sem="disease" ids="C0686619" disease_type="Neoplastic Process" abbrv="">lymph node metastases</z:e> (0.6%) </plain></SENT>
<SENT sid="7" pm="."><plain>Seventy-five patients (46%) had complications </plain></SENT>
<SENT sid="8" pm="."><plain>Seven of 9 <z:hpo ids='HP_0011420'>deaths</z:hpo> within 6 months were esophagectomy related, 6 from <z:hpo ids='HP_0002093'>respiratory failure</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Seven patients had recurrence, <z:hpo ids='HP_0000001'>all</z:hpo> within 4 years </plain></SENT>
<SENT sid="10" pm="."><plain>Five-, 10-, and 15-year survivals were 82%, 69%, and 60%, respectively, which were similar to those of a matched general population </plain></SENT>
<SENT sid="11" pm="."><plain>Determinants of late mortality were older age (P = .004), poorer lung function (P &lt; .0001), longer <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (P = .04), postoperative <z:hpo ids='HP_0002090'>pneumonia</z:hpo> (P = .06), <z:e sem="disease" ids="C0920420" disease_type="Neoplastic Process" abbrv="">cancer recurrence</z:e> (P &lt; .0001), and <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">second cancers</z:e> (P &lt; .0001) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Survival after esophagectomy for intramucosal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> is excellent, determined more by patient than <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> characteristics </plain></SENT>
<SENT sid="13" pm="."><plain>Patient selection and respiratory function are crucial to minimize harm </plain></SENT>
<SENT sid="14" pm="."><plain>Considering the outcome of emerging therapies, esophagectomy should be reserved for patients with a long intramucosal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> or those in whom endoscopic therapies fail or are inappropriate </plain></SENT>
</text></document>